US semaglutide market estimated at $24.1 billion in 2026 as generic rivals stay abroad

The U.S. semaglutide market is estimated at $24.10 billion in 2026, about 61.2% of global revenue for the drug, according to a Fortune Business Insights market forecast ^[1]. The same report estimates the global semaglutide market at $39.37 billion in 2026, up from $34.52 billion in 2025, and projects $86.05 billion by 2034, a 10.27% annual growth rate over that period ^[1].

Semaglutide is the molecule in Novo Nordisk's Ozempic, Wegovy and Rybelsus ^[1]. North America held 69.09% of the global semaglutide market in 2025, when regional sales reached $23.85 billion ^[1]. The report projects Europe at $6.61 billion in 2026, Asia Pacific at $4.67 billion, and Japan at $1.11 billion, about 2.81% of global revenue ^[1]. Ozempic is the largest product by revenue, and type 2 diabetes is the largest disease indication ^[1].

In the United States, semaglutide remains protected from generic competition until 2032 ^[2]. Patent expirations in India, Canada, Brazil and China this year are expected to have a sizable impact on revenue ^[2]. India's patent expired, and at least five domestic manufacturers launched generic versions over one weekend, undercutting Novo Nordisk's price by up to 80% ^[2]. Sun Pharmaceutical priced a weekly injection at 750 rupees, about $8, or roughly 3,400 rupees a month, against Novo's retail price of 8,800 to 10,000 rupees depending on dose ^[2]. Natco Pharma sells a vial formulation at 1,250 rupees a month, and Alkem Laboratories has prefilled injections starting at 1,800 rupees a month ^[2]. More than 50 brands are expected to launch generic semaglutide in India in coming months ^[2].

Novo Nordisk warned in February that sales could decline by 5% to 13% in 2026 ^[2]. That same month, the company announced a significant reduction in the U.S. list price of Wegovy, Ozempic and Rybelsus ^[1]. In January 2026, an oral Wegovy pill for weight loss in adults became available across the U.S. through more than 70,000 pharmacies ^[1]. In March 2026, Novo partnered with Hims, Inc. and said it would offer compounded semaglutide through that platform on a limited scale ^[1]. Novo cut the price of Wegovy in India by 37% in December 2025, before the patent expired ^[2].

Why it matters for patients

Generic competition is not expected to change U.S. supply of semaglutide before 2032, because exclusivity runs that long ^[2]. The cheaper copies launching this year apply to India, Canada, Brazil and China ^[2]. Novo Nordisk's U.S. list-price reductions cover Wegovy, Ozempic and Rybelsus ^[1]; how those list prices affect what an individual patient pays at the pharmacy has not been disclosed in these reports.

The FDA-approved Wegovy label states that 73% of Wegovy-treated adults in weight-reduction trials reported gastrointestinal adverse reactions, compared with 47% on placebo, with severe reactions reported in 4.1% of Wegovy patients versus 0.9% on placebo ^[1]. The market report lists gastrointestinal side effects and high treatment costs as factors that can lead patients to delay dose increases, stop treatment early, or avoid it entirely, and says cost remains a barrier particularly for uninsured people ^[1].

What happens next

Patent expirations in Canada, Brazil and China are expected this year ^[2]. Dr. Reddy's Laboratories plans to expand its generic semaglutide to Canada, Turkey and Brazil this year and is targeting annual sales of 12 million pens in the first year across all markets ^[2]. Novo Nordisk has guided to a 5% to 13% sales decline in 2026 ^[2]. Analysts told CNBC that Novo could keep a large share of the Indian market if it holds a 15% to 20% premium over generics, but whether it keeps its leading position there is not yet clear ^[2]. The forecast projects global semaglutide revenue reaching $86.05 billion by 2034 ^[1].